Skip to main content
Program
Login Required
Poster Gallery
Browse by Category
Browse by Poster Number
Browse by Title
Browse by Author
Poster Wall
Sponsors
Exhibits
Exhibit Hall
Exhibitor List
Restricted Access
Delegates
Speakers
Attendees
CE Information/Evaluation
CE Information
Faculty Disclosures
Evaluation/Claim CE
iwCLL Committees & Membership
FAQ
Toggle navigation
Login
Search
Home
Program
Login Required
Poster Gallery
Browse by Category
Browse by Poster Number
Browse by Title
Browse by Author
Poster Wall
Sponsors
Exhibits
Exhibit Hall
Exhibitor List
Restricted Access
Delegates
Speakers
Attendees
CE Information/Evaluation
CE Information
Faculty Disclosures
Evaluation/Claim CE
iwCLL Committees & Membership
FAQ
iwCLL X / Twitter
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Poster Title
Home
Browse by Poster Title
Browse by Poster Title
8 results found
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
V
1211
Venetoclax as an Alternative and Effective Treatment in Central Nervous System Involvement of Chronic Lymphocytic Leukemia: Monocentric Experience
Past, Present, and Future in CLL
Favorite
1115
Venetoclax Consolidation after BTKi Based Therapy for Patients with CLL
Therapy of CLL
Favorite
1034
Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Clinical Challenges in CLL
Favorite
2015
VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Therapy of CLL
Favorite
4003
VENETOCLAX TREATMENT OF REFRACTORY ITP IN CLL
Clinical Challenges in CLL
Favorite
2017
Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Therapy of CLL
Favorite
1130
Vertebral fractures in patients with B-cell chronic lymphocytic leukemia before and after ibrutinib treatment
Clinical Challenges in CLL
Favorite
1132
Very low COVID mortality and hospitalization rates in CLL and MBL with repeated vaccination to maximum antibody response
Past, Present, and Future in CLL
Favorite
Back to Top